Document:

Exhibit

Exhibit 4.3

GLOBAL BLOOD THERAPEUTICS, INC. 

FIRST AMENDMENT TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

This First Amendment (the “Amendment”) to Amended and Restated Investors’ Rights Agreement is made and entered into as of January 26, 2016 by and among Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned Investors.  All capitalized terms used herein and not otherwise defined shall have the meanings assigned to them in the Agreement (as defined below).

WHEREAS, the Company and the Investors previously entered into that certain Amended and Restated Investors’ Rights Agreement, dated December 22, 2014 (the “Agreement”);

WHEREAS, under Section 6.6 of the Agreement, the Agreement may be amended only with the written consent of the Company and the holders of at least sixty-six and two-thirds percent (66 2/3%) of the Registrable Securities held by the Investors (collectively, the “Requisite Vote”); 

WHEREAS, the undersigned represent the Requisite Vote, and such parties desire to amend the Agreement to clarify and amend the definition of “Registrable Securities” thereunder as set forth herein.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby confirmed, the Company and the undersigned Investors, on behalf of themselves and all Investors (and any assignees thereof) agree that the Agreement is amended as follows:
1.Section 1.21 of the Agreement is hereby amended and restated in its entirety as follows:
“1.21    “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Series A Preferred Stock and the Series B Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, held by the Investors or acquired by a holder of Series A Preferred Stock or Series B Preferred Stock after the date hereof; (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; and (iv) any other Common Stock subsequently acquired by an Investor, without duplication of any securities referred to in clauses (i) through (iii) hereof; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for 

GDSVF&H\    
ACTIVE/84513179.1

which registration rights have terminated pursuant to Section 2.13 of this Agreement.”
2.Continued Validity of Agreement.  Except as specifically amended hereby, the Agreement shall continue in full force and effect as originally constituted and is ratified and affirmed by the parties hereto.
3.Successors and Assigns.  The provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors and administrators and other legal representatives.
4.Counterparts.  This Amendment may be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
5.Governing Law.  This Amendment shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of State of California, without regard to conflict of law principles that would result in the application of any law other than the law of the State of California.  
[Remainder of page intentionally left blank.]
IN WITNESS WHEREOF, the undersigned parties have executed this Amendment as of the day and year first above written.

	
	
	THE COMPANY:

GLOBAL BLOOD THERAPEUTICS, INC.

By:   /s/ Ted W. Love         
Name: Ted W. Love, M.D.
Title: President and Chief Executive Officer

	 

	 

IN WITNESS WHEREOF, the undersigned parties have executed this Amendment as of the day and year first above written.

INVESTOR:

THIRD ROCK VENTURES  II, L.P.  

By:  Third Rock Ventures GP  II, L.P., its general partner  
By:  TRV GP II, LLC, its general partner

By:_/s/ Kevin Gillis________________ 
      Name: Kevin Gillis 
      Title:   CFO

THIRD ROCK VENTURES  III, L.P.  

By:  Third Rock Ventures GP  III, L.P., its general partner  
By:  TRV GP III, LLC, its general partner

By:_/s/ Kevin Gillis________________ 
      Name: Kevin Gillis 
      Title:   CFO

SIGNATURE PAGE TO GLOBAL BLOOD THERAPEUTICS, INC.
FIRST AMENDMENT TO THE AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

IN WITNESS WHEREOF, the undersigned parties have executed this Amendment as of the day and year first above written.

INVESTOR:

FIDELITY SELECT PORTFOLIOS:
BIOTECHNOLOGY PORTFOLIO  

By:_/s/ Joseph Zambello____________ 
      Name: Joseph Zambello 
      Title:   Deputy Treasurer

FIDELITY ADVISOR SERIES VII: FIDELITY ADVISOR BIOTECHNOLOGY FUND  

By:_/s/ Joseph Zambello_____________ 
      Name: Joseph Zambello 
      Title:   Deputy Treasurer

 

SIGNATURE PAGE TO GLOBAL BLOOD THERAPEUTICS, INC.
FIRST AMENDMENT TO THE AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTExhibit

Exhibit 10.5

 

GLOBAL BLOOD THERAPEUTICS, INC.
400 EAST JAMIE COURT, SUITE 101 
SOUTH SAN FRANCISCO, CA 94080

June 18, 2014

Hing Leung Sham, Ph.D.

Dear Hing,

Global Blood Therapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms:

1.Position.  Your initial title will be Senior Vice President, Chemistry, and you will initially report to Uma Sinha. This is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company.  By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.

2.    Cash Compensation.  The Company will pay you a starting salary at the rate of $300,000 per year, payable in accordance with the Company’s standard payroll schedule.  This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time to time. In addition to your salary, you will be eligible to participate in the Annual Performance-Based Cash Incentive Award Program which is based on the achievement of Company performance goals and your personal goals to be set with your manager.

3.    Employee Benefits.  As a regular employee of the Company, you will be eligible to participate in a number of Company-sponsored benefits.  Should you decide to participate in the Company health benefits program, your coverage will begin the first day of the month following your start date. In addition, you will be entitled to 20 days of paid time off in accordance with the Company’s policy.

4.    Stock Options.  Subject to the approval of the Company’s Board of Directors or its Compensation Committee, you will be granted an option to purchase 300,000 shares of the Company’s Common Stock.  The exercise price per share will be determined by the Board of Directors or the Compensation Committee when the option is granted.  The option will be subject to the terms and conditions applicable to options granted under the Company’s 2012 Stock Plan (the “Plan”), as described in the Plan and the applicable stock option agreement. You will vest in 25% of the option shares after 12 months of continuous service, and the balance will vest in equal quarterly installments over the next 36 months of continuous service, as described in the applicable stock option agreement.

5.    Employee Confidentiality and Assignment Agreement.  Like all Company employees, you will be required, as a condition of your employment with the Company, to sign the Company’s standard Employee Confidentiality and Assignment Agreement, a copy of which is attached hereto as Exhibit A.

6.    Background Check. The Company may conduct a background or reference check (or both).  If so, then you agree to cooperate fully in those procedures, and this offer is subject to the Company’s approving the outcome of those checks, in the discretion of the Company.

7.    Employment Relationship.  Employment with the Company is for no specific period of time.  Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause.  Any contrary representations that may have been made to you are superseded by this letter agreement.  This is the full and complete agreement between you and the Company on this term.  Although your job duties, title, reporting relationship, compensation and benefits, as well as the Company’s personnel policies and procedures, may 

1

change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).

8.    Taxes.  All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.  You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation.

9.    Interpretation, Amendment and Enforcement.  This letter agreement and Exhibit A constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.  This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company.  The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company will be governed by California law, excluding laws relating to conflicts or choice of law.

* * * * *

We hope that you will accept our offer to join the Company.  You may indicate your agreement with these terms and accept this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Proprietary Information and Inventions Agreement and returning them to me.  This offer, if not accepted, will expire at the close of business on June 23, 2014.  As required by law, your employment with the Company is contingent upon your providing legal proof of your identity and authorization to work in the United States.  Your employment is also contingent upon your starting work with the Company on July 28, 2014.

If you have any questions, please call me at 650-741-7720.

Very truly yours,

/s/ Ted W. Love

Ted W. Love, M.D.
Chief Executive Officer
GLOBAL BLOOD THERAPEUTICS, INC.

I have read and accept this employment offer:

                /s/ Hing Leung Sham             
Hing Leung Sham, Ph.D.

Dated:  6/19/2014    

Attachment
Exhibit A: Employee Confidentiality and Assignment Agreement

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]